Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
David HappelPresident & CEO | Sagimet BiosciencesSGMT | Open-market sale | 02/10 | 02/12 | 12,101 sh | $5.36 | $64,861.36 | −1.8% |
Eduardo Bruno MartinsChief Medical Officer | Sagimet BiosciencesSGMT | Open-market sale | 02/10 | 02/12 | 3,640 sh | $5.36 | $19,510.4 | −3.4% |
Sagimet BiosciencesSGMT | Open-market sale | 02/10 | 02/12 | 1,312 sh | $5.36 | $7,032.32 | −7.7% | |
Elizabeth RozekChief Legal & Admin. Officer | Sagimet BiosciencesSGMT | Open-market sale | 02/10 | 02/12 | 2,622 sh | $5.36 | $14,053.92 | −1.4% |
George KembleExecutive Chairman | Sagimet BiosciencesSGMT | Open-market sale10b5-1 plan | 25/11/20 | 25/11/21 | 37,688 sh | $7.69 | $289,820.72 | −31.8% |
David HappelPresident & CEO | Sagimet BiosciencesSGMT | Open-market sale | 25/07/21 | 25/07/23 | 65,478 sh | $9.13 | $597,814.14 | −8.7% |
Eduardo Bruno MartinsChief Medical Officer | Sagimet BiosciencesSGMT | Open-market sale | 25/07/21 | 25/07/23 | 8,277 sh | $9.13 | $75,569.01 | −7.2% |
Elizabeth RozekGeneral Counsel and CCO | Sagimet BiosciencesSGMT | Open-market sale | 25/07/21 | 25/07/23 | 10,780 sh | $9.13 | $98,421.4 | −5.5% |
George KembleExecutive Chairman | Sagimet BiosciencesSGMT | Open-market sale10b5-1 plan | 24/07/23 | 24/07/25 | 23,625 sh | $3.17 | $74,891.25 | −16.6% |
Eduardo Bruno MartinsChief Medical Officer | Sagimet BiosciencesSGMT | Open-market sale | 24/07/19 | 24/07/23 | 8,357 sh | $3.10 | $25,906.7 | −9.3% |
George KembleExecutive Chairman | Sagimet BiosciencesSGMT | Open-market sale | 24/07/19 | 24/07/23 | 14,062 sh | $3.10 | $43,592.2 | −9.0% |
Elizabeth RozekGeneral Counsel and CCO | Sagimet BiosciencesSGMT | Open-market sale | 24/07/19 | 24/07/23 | 10,914 sh | $3.10 | $33,833.4 | −6.4% |
David HappelPresident & CEO | Sagimet BiosciencesSGMT | Open-market buy | 24/03/26 | 24/03/28 | 12,100 sh | $5.27 | $63,767 | +1.9% |
David HappelPresident & CEO | Sagimet BiosciencesSGMT | Open-market buy | 23/12/07 | 23/12/08 | 1,600 sh | $4.10 | $6,560 | +0.3% |
David HappelPresident & CEO | Sagimet BiosciencesSGMT | Open-market buy | 23/11/16 | 23/11/20 | 590 sh | $2.35 | $1,386.5 | No record |
Beth C. SeidenbergDirector | Sagimet BiosciencesSGMT | Open-market buy | 23/07/18 | 23/07/20 | 46,875 sh | $16.00 | $750,000 | No record |
Patrick J. Kerins10% Owner | Sagimet BiosciencesSGMT | Open-market buy | 23/07/18 | 23/07/20 | 30,000 sh | $16.00 | $480,000 | +0.8% |
Patrick J. Kerins10% Owner | Sagimet BiosciencesSGMT | Open-market sale | 23/07/18 | 23/07/20 | 662 sh | $16.00 | $10,592 | −0.0% |
Scott D. Sandell10% Owner | Sagimet BiosciencesSGMT | Open-market buy | 23/07/18 | 23/07/20 | 30,000 sh | $16.00 | $480,000 | +0.8% |
Scott D. Sandell10% Owner | Sagimet BiosciencesSGMT | Open-market sale | 23/07/18 | 23/07/20 | 662 sh | $16.00 | $10,592 | −0.0% |